Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

0.4140 -0.0280 (-6.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 934,065
Open 0.4461
Bid (Size) 0.4150 (1,600)
Ask (Size) 0.4485 (200)
Prev. Close 0.4420
Today's Range 0.4140 - 0.4529
52wk Range 0.3700 - 8.940
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
Via ACCESS Newswire
News headline image
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market 
From Medicus Pharma Ltd
Via GlobeNewswire

Performance

YTD
-74.1%
-74.1%
1 Month
-14.7%
-14.7%
3 Month
-73.3%
-73.3%
6 Month
-83.3%
-83.3%
1 Year
-87.6%
-87.6%

More News

Read More
News headline image
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
From Medicus Pharma Ltd
Via GlobeNewswire
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026
Via AB Newswire
News headline image
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Via ACCESS Newswire
News headline image
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
Via ACCESS Newswire
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Via ACCESS Newswire
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
American Lithium Minerals (OTC: AMLM) Targets Tokenized Commodities Opportunity Alongside MDCX, ASNS, EONR, ELPW Today!
Via AB Newswire
Topics Artificial Intelligence
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
Via ACCESS Newswire
Here are the top movers in Friday's session. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma To Participate in the 38th Annual Roth Conference
From Medicus Pharma Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?
Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.
What exchange does Medicus Pharma Ltd. - Common Stock trade on?
Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?
The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market
What is the current price of Medicus Pharma Ltd. - Common Stock?
The current price of Medicus Pharma Ltd. - Common Stock is 0.4140
When was Medicus Pharma Ltd. - Common Stock last traded?
The last trade of Medicus Pharma Ltd. - Common Stock was at 04/10/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.